TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately.
About Acerus
Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health.
Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.
Company Contact
Naveed Manzoor
Chief Financial Officer
ir@aceruspharma.com
RFID-Enabled Dispensing and Intelligent Inventory Management Software Aim to Unlock Greater Inventory Accuracy and Streamline…
Marpai's turnaround momentum is building TAMPA, Fla., May 14, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or…
ARLINGTON, Va., May 14, 2025 /PRNewswire/ -- Osteoporosis, a disease that causes bones to become…
MUMBAI, India, May 14, 2025 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a…
MILWAUKEE, May 14, 2025 /PRNewswire/ -- Hammes, a national real estate consulting, development, investment and…
Existing senior secured credit facility assigned to new investors; added $1.6 million of new senior…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
